•
Sep 30, 2024

The Joint Q3 2024 Earnings Report

The Joint Corp. reported Q3 2024 financial results.

Key Takeaways

The Joint Corp. reported a 2% increase in revenue to $30.2 million, but net loss was $3.2 million, including $3.8 million in loss on disposition or impairment. System-wide sales increased 8% to $129.3 million.

Revenue grew 2% to $30.2 million.

Net loss was $3.2 million, including $3.8 million in loss on disposition or impairment.

Adjusted EBITDA was $2.4 million.

System-wide sales increased 8% to $129.3 million.

Total Revenue
$30.2M
Previous year: $29.5M
+2.5%
EPS
$0.04
Previous year: -$0.05
-180.0%
Total Clinic Count
963
Gross Profit
$27.4M
Previous year: $26.9M
+1.9%
Cash and Equivalents
$20.7M
Previous year: $16.1M
+28.8%
Free Cash Flow
$3.2M
Previous year: $2.7M
+18.7%
Total Assets
$79.6M
Previous year: $98.6M
-19.2%

The Joint

The Joint

The Joint Revenue by Segment

Forward Guidance

The company adjusted its guidance to account the potential impact of ongoing consumer headwinds.

Positive Outlook

  • System-wide sales are expected to be between $525 million and $535 million.
  • System-wide comp sales for all clinics open 13 months or more are expected to be between 3% and 4%.
  • New franchised clinic openings, excluding the impact of refranchised clinics, are expected to be between 55 and 60.

Revenue & Expenses

Visualization of income flow from segment revenue to net income